| Literature DB >> 35845924 |
Zhen Yao1, Xue Pan1, Wenyue Chen2, Yongjian Pei1, Chen Chen1, Yongkang Huang1, Songtao Liu3, Yulong Liu2,4.
Abstract
Background: Colorectal cancer (CRC), one of the main causes of death, remains a leading cause of mortality in gastrointestinal cancer and tends to affect the younger generation. However, the pathological process of colorectal cancer is unclear. Exploring potential pathogenesis and therapeutic targets of CRC is significant as its high prevalence and high mortality. Nowadays, the rapid development of bioinformatics provides us an opportunity to explore potential molecular markers of CRC. Materials andEntities:
Mesh:
Year: 2022 PMID: 35845924 PMCID: PMC9279071 DOI: 10.1155/2022/3149887
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.246
Information on normalization of microarray data.
| Dataset name | Platform | Type of experiment | CRC | Normal | Total |
|---|---|---|---|---|---|
| GSE10950 | GPL6104 | Expression profiling by array | 24 | 24 | 48 |
| GSE44076 | GPL13667 | Expression profiling by array | 98 | 98 | 196 |
| GSE75970 | GPL14550 | Expression profiling by array | 4 | 4 | 8 |
| Total | 126 | 126 | 252 |
Sequences of the three siRNAs.
| siRNA | siRNA sequence information |
|---|---|
| si-CXCL8-1 | AAAGCUUUACAAUAAUUUCUGUU |
| si-CXCL8-2 | AGUUCUUUGAUAAAUUUGGGGUU |
| si-CXCL8-3 | AGCUUUACAAUAAUUUCUGUGUU |
qRT-PCR primer pairs.
| Name | Primer sequence information |
|---|---|
| GAPDH-F | GAAGGTGAAGGTCGGAGTC |
| GAPDH-R | GAAGATGGTGATGGGATTTC |
| CXCL8-F | TCTGCAGCTCTGTGTGAAGG |
| CXCL8-R | TGGGGTGGAAAGGTTTGGAG |
Scoring system of immunohistochemistry.
| Mark | 0 | 1 | 2 | 3 | 4 |
|---|---|---|---|---|---|
| Dyeing intensity | Not stained | Light yellow | Medium brownish yellow | Strong brownish brown | |
| Staining range | <5.0% | 5.0%~25.0% | 26.0%~50.0% | 51.0%~75.0% | >75.0% |
Final score = staining intensity∗staining range (positive product ≥ 3 and negative product<3).
Figure 1(a) Heat map. (b) Volcano map.
Figure 2(a) Bar chart of GO enrichment analysis. (b) Bar chart of KEGG enrichment analysis.
Figure 3(a) Protein interaction network. (b) Rank of core genes.
Figure 4Survival curve.
Figure 5The expression and function of CXCL8 in colorectal cancer. (a) The expression of CXCL8 in various colorectal cancer cell lines (∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001). (b) The expression of CXCL8 in colorectal cancer cells detected by QRT PCR (SW480) (∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001). (c) Cell counting kit-8 assay (SW480) (∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001).
Figure 6Wound healing assay (SW480) (∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001).
Figure 7Transwell migration assays (SW480) (∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001).
Figure 8Transwell invasion assays (SW480) (∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001).
Specific distribution of pathological chips.
| 1 T | 11T | 21 T | 31 T | 41 T | 51 T | 61 T | 1 N | 11 N | 21 N | 31 N | 41 N | 51 N |
| 2 T | 12 T | 22 T | 32 T | 42 T | 52 T | 62 T | 2 N | 12 N | 22 N | 32 N | 42 N | 52 N |
| 3 T | 13 T | 23 T | 33 T | 43 T | 53 T | 63 T | 3 N | 13 N | 23 N | 33 N | 43 N | 53 N |
| 4 T | 14 T | 24 T | 34 T | 44 T | 54 T | 64 T | 4 N | 14 N | 24 N | 34 N | 44 N | 54 N |
| 5 T | 15 T | 25 T | 35 T | 45 T | 55 T | 5 N | 15 N | 25 N | 35 N | 45 N | 55 N | |
| 6 T | 16 T | 26 T | 36 T | 46 T | 56 T | 61 N | 6 N | 16 N | 26 N | 36 N | 46 N | 56 N |
| 7 T | 17 T | 27 T | 37 T | 47 T | 57 T | 62 N | 7 N | 17 N | 27 N | 37 N | 47 N | 57 N |
| 8 T | 18 T | 28 T | 38 T | 48 T | 58 T | 63 N | 8 N | 18 N | 28 N | 38 N | 48 N | 58 N |
| 9 T | 19 T | 29 T | 39 T | 49 T | 59 T | 64 N | 9 N | 19 N | 29 N | 39 N | 49 N | 59 N |
| 10 T | 20 T | 30 T | 40 T | 50 T | 60 T | 10 N | 20 N | 30 N | 40 N | 50 N | 60 N |
T: tumor tissue; N: normal tissue.
Figure 9Immunohistochemical results. (a) Negative result of CXCL8 in normal tissue adjacent to carcinoma. (b) Negative result of CXCL8 in CRC. (c) CXCL8 dyed in the nucleus. (d) CXCL8 dyed in nucleus and cytoplasm.
Relationship between CXCL8 expression and clinicopathological features of colorectal cancer.
| Grouping | CXCL8 expression |
| |
|---|---|---|---|
| — | + | ||
| Gender ( | |||
| Male | 29 (74.4%) | 10 (25.6%) |
|
| Female | 21 (84.0%) | 4 (16.0%) | |
| Age ( | |||
| ≤66 | 23 (71.9%) | 9 (28.1%) |
|
| >66 | 27 (84.4%) | 5 (15.6%) | |
| Location 1 ( | |||
| Colon | 31 (73.8%) | 11 (26.2%) |
|
| Rectum | 19 (86.4%) | 3 (13.6%) | |
| Location 2 ( | |||
| Left colon | 13 (68.4%) | 6 (31.6%) |
|
| Right colon | 16 (76.2%) | 5 (23.8%) | |
| Differentiation ( | |||
| High | 3 (100.0%) | 0 (0.0%) |
|
| Moderate | 43 (78.2%) | 12 (21.8%) | |
| Low | 4 (66.7%) | 2 (33.3%) | |
| T stage ( | |||
| T2 | 6 (100.0%) | 0 (0.0%) |
|
| T3 | 26 (72.2%) | 10 (27.8%) | |
| T4 | 18 (81.8%) | 4 (18.2%) | |
| N stage ( | |||
| No metastasis | 30 (93.8%) | 2 (6.3%) |
|
| Metastasis | 20 (62.5%) | 12 (37.5%) | |
| M stage ( | |||
| No metastasis | 43 (79.6%) | 11 (204%) |
|
| Metastasis | 7 (70.0%) | 3 (30.0%) | |
| Intravascular tumor thrombus ( | |||
| No | 42 (84.0%) | 8 (16.0%) |
|
| Yes | 8 (51.7%) | 6 (42.9%) | |
| AJCC stage ( | |||
| I | 4 (100.0%) | 0 (0.0%) |
|
| II | 24 (88.9%) | 3 (11.1%) | |
| III | 15 (65.2%) | 8 (34.8%) | |
| IV | 7 (70.0%) | 3 (30.0%) | |